The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Self-citationDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Self-citationDeacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Self-citationAhrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Self-citationThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Self-citationT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Plasma systemic concentrations of “intact”, biologically active GLP-1 are much lower (fasting: < 2 pmol/l, peak post-nutrient concentrations 5e10 pmol/l) [240,242].”
BackgroundSelf-citationβ-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
The incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515
Self-citationSecretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
“Since the latter are thought to exert their glucose-lowering activity by preventing the degradation and inactivation (with regard to insulinotropic effects) of endogenously released intact, biologically active GLP-1 [9], their pharmacological action should critically depend on availability of the major substrate, GLP-…”
BackgroundSelf-citationPhysiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428
Self-citationEnteroendocrine cells: a review of their role in brain–gut communication
Latorre, R., Sternini, C., De Giorgio, R., & Greenwood‐Van Meerveld, B. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12754 · Cited by 392
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Reduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
Self-citationKanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347
“Significant main effects of sCT were obtained at 3 h and 6 h [Fs(1,7) 14.”
BackgroundInfluentialFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes
Pi-Sunyer, F. X., Schweizer, A., Mills, D., & Dejager, S. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.12.009 · Cited by 312
Liraglutide for weight management: a critical review of the evidence
Mehta, A., Marso, S. P., & Neeland, I. J. (2017) · Obesity Science & Practice · doi:10.1002/osp4.84 · Cited by 311
Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery
Madsbad, S., Dirksen, C., & Holst, J. J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70218-3 · Cited by 298
Self-citationBile acid signaling pathways from the enterohepatic circulation to the central nervous system
Mertens, K. L., Kalsbeek, A., Soeters, M. R., & Eggink, H. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00617 · Cited by 287
Chang, C. L. T., Lin, Y., Bartolome, A. P., Chen, Y.-C., Chiu, S.-C., & Yang, W.-C. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/378657 · Cited by 274
Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes
Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., & Schweizer, A. (2007) · Diabetes Care · doi:10.2337/dc06-1815 · Cited by 270
Bauer, P. V., Duca, F. A., Waise, T. M. Z., Rasmussen, B. A., Abraham, M. A., Dranse, H. J., Puri, A., O’Brien, C. A., & Lam, T. K. T. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.019 · Cited by 265
GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesity
Overton, H. A., Fyfe, M. C. T., & Reynet, C. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707529 · Cited by 264
Rüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N., & Langhans, W. (2009) · Endocrinology · doi:10.1210/en.2008-1221 · Cited by 258
Glucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake
Dossat, A. M., Lilly, N., Kay, K., & Williams, D. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3262-11.2011 · Cited by 256
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251
“5 min) [50], only ~10% of intact GLP-1 actually reaches the systemic circulation [51], thereby reducing the possibility of detecting a small difference between responses in the peripheral circulation.”
Self-citationThe incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Self-citationPreproglucagon neurons project widely to autonomic control areas in the mouse brain
Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., & Trapp, S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.023 · Cited by 194
“GLP-1 in the bloodstream is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) into an inactive N-terminally truncated form (Kieffer et al., 1995, Holst and Deacon, 2005) and it is unclear whether GLP-1 can cross the blood brain barrier (Orskov et al., 1996, Kastin et al., 2002).”
BackgroundThe L-cell in nutritional sensing and the regulation of appetite
Spreckley, E. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00023 · Cited by 198
Deacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
Self-citationGLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
Shigeto, M., Ramracheya, R., Tarasov, A. I., Cha, C. Y., Chibalina, M. V., Hastoy, B., Philippaert, K., Reinbothe, T., Rorsman, N., Salehi, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81975 · Cited by 189
Role of the glucagon-like-peptide-1 receptor in the control of energy balance
Hayes, M. R., De Jonghe, B. C., & Kanoski, S. E. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.02.029 · Cited by 173
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146
The metabolic role of vagal afferent innervation
Waise, T. M. Z., Dranse, H. J., & Lam, T. K. T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0062-1 · Cited by 140
Is GLP‐1 a hormone: Whether and When?
D'Alessio, D. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12466 · Cited by 130
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“…thought that GLP-1 mainly acts by activating GLP-1Rs on sensory afferents of the vagus nerve, which densely express GLP-1Rs in the nodose ganglion (which harbours cell bodies of vagal sensory neurons), or in neurons of the enteric nervous system, which may relay the signals to the CNS 234 .”
InfluentialSelf-citationRonveaux, C. C., Tomé, D., & Raybould, H. E. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206029 · Cited by 124
“DDP-IV is abundant in the brush border and endothelial cells that line the capillaries (14, 15).”
GLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
Gonzalez, J. T., Veasey, R. C., Rumbold, P. L. S., & Stevenson, E. J. (2013) · British Journal of Nutrition · doi:10.1017/s0007114512005582 · Cited by 108
“It should be noted that GLP-17–36 may interact with neurons expressed locally in L-cells, prior to being rapidly degraded on entry into the circulation, where its clearance can exceed cardiac output by two to three times((44)).”
McKay, N. J., Kanoski, S. E., Hayes, M. R., & Daniels, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00472.2011 · Cited by 79
McKay, N. J., Galante, D. L., & Daniels, D. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3267-14.2014 · Cited by 55
“Second, although we found no change in plasma GLP-1 levels after manipulations in water intake, a small magnitude effect could have been obscured by rapid degradation of GLP-1 in circulation (Holst and Deacon, 2005).”
BackgroundMcLaughlin, C. M., Harnedy-Rothwell, P. A., Lafferty, R. A., Sharkey, S., Parthsarathy, V., Allsopp, P. J., McSorley, E. M., FitzGerald, R. J., & O’Harte, F. P. M. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02583-3 · Cited by 45
Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review
Watkins, J. D., Koumanov, F., & Gonzalez, J. T. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab078 · Cited by 40
Effect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test
Salehi, M., Aulinger, B., & D’Alessio, D. A. (2012) · Diabetes · doi:10.2337/db11-1825 · Cited by 38
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Metadata
- Authors
- Holst, J. J., & Deacon, C. F.
- Venue
- Diabetologia
- Published
- 2005-03-10
- Volume
- 48
- Issue
- 4
- Pages
- 612-615
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054649558
- Cited by
- 288
- References
- 34
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.